Based on the Genomics of Drug Sensitivity in Cancer (GDSC) data, similar trends were also observed, for the same KRAS mutant cell lines, with the MEK and ERK inhibitors Trametinib, ERK-6604, ERK-2440 and Ulixertinib (Figure 2). This evidence concerns the gene KRAS and cancer.